Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 22 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-8.24 Insider Own- Shs Outstand3.79M Perf Week-1.55%
Market Cap19.89M Forward P/E- EPS next Y-1.39 Insider Trans- Shs Float- Perf Month-7.97%
Income-22.15M PEG- EPS next Q-1.09 Inst Own7.31% Short Float- Perf Quarter-0.52%
Sales0.07M P/S284.12 EPS this Y69.14% Inst Trans-50.17% Short Ratio1.53 Perf Half Y-50.30%
Book/sh-1.25 P/B- EPS next Y44.60% ROA-126.90% Short Interest0.05M Perf Year-77.59%
Cash/sh1.07 P/C3.56 EPS next 5Y- ROE-1239.54% 52W Range2.82 - 18.50 Perf YTD-44.44%
Dividend Est.- P/FCF- EPS past 5Y-18.88% ROI-391.68% 52W High-79.41% Beta-0.22
Dividend TTM- Quick Ratio1.18 Sales past 5Y0.00% Gross Margin- 52W Low34.90% ATR (14)0.24
Dividend Ex-Date- Current Ratio1.18 EPS Y/Y TTM15.91% Oper. Margin-30196.19% RSI (14)48.89 Volatility5.78% 5.82%
Employees49 Debt/Eq- Sales Y/Y TTM- Profit Margin-30099.83% Recom1.00 Target Price9.67
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q41.87% Payout- Rel Volume0.74 Prev Close3.57
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsApr 02 BMO Avg Volume34.83K Price3.81
SMA20-2.33% SMA503.02% SMA200-40.26% Trades Volume25,995 Change6.72%
Date Action Analyst Rating Change Price Target Change
Apr-02-24Upgrade Ladenburg Thalmann Neutral → Buy $8
Feb-12-24Initiated H.C. Wainwright Buy $14
May-10-24 05:00PM
May-07-24 09:15AM
Apr-17-24 08:00AM
Apr-03-24 11:26AM
07:00AM Loading…
Apr-02-24 07:00AM
Mar-27-24 07:30AM
Mar-19-24 07:30AM
Feb-29-24 07:30AM
Feb-20-24 07:30AM
Feb-07-24 08:30AM
Feb-06-24 08:30AM
Feb-01-24 09:20AM
Jan-24-24 08:30AM
Jan-22-24 04:30PM
08:30AM Loading…
Jan-08-24 08:30AM
Dec-21-23 04:30PM
Dec-19-23 04:15PM
Nov-28-23 08:27AM
Nov-15-23 08:00AM
Nov-06-23 10:12AM
Oct-31-23 11:15AM
Oct-26-23 08:30AM
Oct-05-23 08:30AM
Sep-21-23 01:23PM
Sep-20-23 08:26AM
Sep-18-23 08:23AM
Sep-11-23 08:17AM
Aug-29-23 08:30AM
09:19AM Loading…
Aug-23-23 09:19AM
Aug-18-23 11:57AM
Aug-01-23 07:00AM
Jul-31-23 07:00AM
Jun-05-23 11:50AM
Jun-03-23 05:00PM
Jun-01-23 06:53AM
May-31-23 08:30AM
May-25-23 05:00PM
May-16-23 05:47AM
Apr-27-23 07:00AM
Apr-18-23 08:00AM
Apr-13-23 09:44AM
Mar-28-23 07:46AM
Mar-23-23 07:55AM
Mar-14-23 04:30PM
Feb-08-23 10:47AM
Jan-19-23 08:45AM
Jan-03-23 08:14AM
Dec-15-22 07:48AM
Dec-06-22 08:18AM
Nov-17-22 11:03AM
Nov-14-22 07:13AM
Nov-10-22 04:10AM
Oct-11-22 11:54AM
Oct-05-22 08:32AM
Sep-22-22 10:50AM
Sep-21-22 05:45AM
Sep-06-22 07:02AM
Aug-10-22 07:00AM
Aug-02-22 07:00AM
Jul-29-22 05:46PM
Jun-30-22 07:00AM
Jun-23-22 12:10PM
Jun-08-22 09:55AM
Jun-07-22 08:05AM
May-11-22 07:30AM
May-10-22 07:30AM
Apr-29-22 12:16PM
Apr-26-22 08:45AM
Apr-06-22 07:30AM
Mar-22-22 06:30AM
Mar-14-22 07:00AM
Mar-07-22 07:30AM
Jan-26-22 07:30AM
Jan-25-22 10:00AM
Jan-21-22 02:30AM
Jan-18-22 08:00AM
Dec-29-21 08:44AM
Nov-09-21 05:00PM
Nov-05-21 06:00AM
Nov-04-21 07:05AM
Nov-01-21 08:17AM
Oct-26-21 07:49AM
Oct-25-21 05:30AM
Oct-14-21 07:30AM
Oct-12-21 04:05PM
Sep-21-21 08:34AM
Aug-12-21 06:30AM
Aug-03-21 03:09AM
Jul-08-21 09:10AM
Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Moller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.